Chronic Kidney Disease

The FDA's decision not to approve sotagliflozin as an adjunct in T1D and CKD comes less than 2 months after a negative advisory committee meeting for the application.

A look into how SGLT2 inhibitors, GLP-1 RAs, and nsMRAs have redefined the management of cardio-kidney-metabolic diseases.

Our Endocrinology Month in Review for November 2024 highlights recent headlines in diabetes and endocrinology as well as 5 new episodes of Diabetes Dialogue.

Lowering serum urate level to less than 6 mg/dL was not linked to an elevated risk of severe or end-stage kidney disease progression in patients with gout.

The 11 to 3 vote against the benefit-risk profile of sotagliflozin comes with less than 2 months to go until the December 20, 2024 PDUFA date.

The dapagliflozin group had an average eGFR rate of -2.24 mL/min/1.73 m2 compared to -3.67 mL/min/1.73 m2 in the control group after about 1.5 years of follow-up.

Participants receiving semaglutide had an overall hazard ratio of 0.76 in the composite primary outcome of kidney failure, serious eGFR decline, or death compared to placebo.

New research indicates semaglutide reduced albuminuria and body weight in CKD patients without diabetes, highlighting its potential renal benefits.

After discontinuing therapy, treated participants still had an overall 13% reduction in the risk of kidney disease progression or cardiovascular death.

New FINEARTS-HF data shows that finerenone reduces albuminuria in patients with HFmrEF or HFpEF, but without significant eGFR changes.

RIVUR analysis suggests recurrent UTIs in children with VUR may lower eGFR, even without kidney scarring, especially in those with multiple febrile infections.

This retrospective analysis examined the current management of early and late anemia in a representative sample of the kidney transplant population in Spain.

Our September 2024 monthly recap in endocrinology spotlights regulatory updates, new guidelines, and the latest episodes of Diabetes Dialogue.

Lack of retinopathy, lower hemoglobin A1c levels, preserved eGFR, microalbuminuria, and lower UPCR were linked to non-DKD.

Leveraging deceased donor kidney transplantation data, study results suggest DCD-V kidney transplantation has similar short- and long-term outcomes versus DCD-III and DBD.

The new guidance reviews existing tools for weight management and provides recommendations for their use in clinical practice in patients with obesity and kidney disease.

A new study found cannabis-containing cream may be effective at alleviating itch in patients with chronic kidney disease (CKD)-associated pruritus with no adverse events.

Vadadustat once-daily demonstrated noninferiority to darbepoetin alfa for the change in mean hemoglobin from baseline, while 3-times-weekly did not.

EMPACT-MI study shows empagliflozin is safe post-acute MI and reduces heart failure events, with kidney protection across kidney function levels.

A meta-analysis shows GLP-1 RAs and SGLT2 inhibitors offer distinct cardiovascular and kidney benefits in type 2 diabetes.

Findings from a recent national registry study suggest perioperative mortality after living kidney donation significantly declined in 2013-2022 compared with 1993-2002 and 2003-2012.

Findings link greater thiazide doses to increased reductions in urine calcium and fewer subsequent symptomatic kidney stone events.

A new real-world study suggests tirzepatide provides greater reductions in mortality, cardiovascular risk, and kidney events than GLP-1 receptor agonists in type 2 diabetes.

Positive topline results from the phase 3 VALIANT study show promise for pegcetacoplan in patients with C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

On August 05, 2024, less than a month prior to its presentation at ESC 24, Bayter has announced topline data from the FINEARTS-HF trial indicating finerenone met the primary endpoint.

The sNDA for furosemide seeks to expand the indication to include the treatment of edema due to fluid overload in patients with CKD, with a PDUFA date of March 6, 2025.

Spigler provides insight into the development of new patient-focused guidelines for managing hyperkalemia in CKD and the importance of providing patients with such resources.

Neuen explains the cardiovascular and kidney benefits of combining SGLT2 inhibitors and GLP-1 receptor agonists in diabetes and the future of combination therapy.

The patient-focused guidelines were developed by the American Kidney Fund and AstraZeneca to help people with CKD manage high potassium.

Findings from a meta-analysis examining 12 trials including more than 70,000 patients with diabetes support combining SGLT2 inhibitors and GLP-1 RAs.